Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02472353 · ClinicalTrials.gov registry record · Phase 2
Use of Metformin to Reduce Cardiac Toxicity in Breast Cancer
A Phase 2 study, sponsored by Avera McKennan Hospital & University Health Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT02472353: Clinical Trial Phase 2 study, sponsored by Avera McKennan Hospital & University Health Center.
NCT02472353 is a Phase 2 study that was terminated before completion, run by Avera McKennan Hospital & University Health Center. The registered enrollment target is 30 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02472353, a Phase 2 study, was terminated before completion, sponsored by Avera McKennan Hospital & University Health Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
The goal of this study is to determine if co-administration of metformin and doxorubicin in breast cancer patients receiving neoadjuvant or adjuvant therapy will reduce the number of patients who develop a significant change in left ventricle ejection fraction (LVEF).
Primary Outcome
Determine whether the addition of metformin to standard doxorubicin therapy in breast cancer patients will decrease the incidence of change in left ventricle ejection fraction (LVEF).
Interventions
- DRUG Doxorubicin
- DRUG Metformin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2014-07 |
| Est. Completion | 2018-05-23 |
| Phase | Phase 2 |
Why NCT02472353 stopped before completion
NCT02472353 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 2 interventions - of which Doxorubicin is the first listed.
NCT02472353 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02472353 about?
NCT02472353 is a clinical study titled "Use of Metformin to Reduce Cardiac Toxicity in Breast Cancer". The goal of this study is to determine if co-administration of metformin and doxorubicin in breast cancer patients receiving neoadjuvant or adjuvant therapy will reduce the number of patients who develop a significant change in left ventricle ejection fraction (LVEF).
What is the current status of trial NCT02472353?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2014-07. Estimated completion is 2018-05-23.
What interventions are being tested in trial NCT02472353?
The interventions under investigation include: Doxorubicin (DRUG), Metformin (DRUG).
Who is sponsoring clinical trial NCT02472353?
This trial is sponsored by Avera McKennan Hospital & University Health Center, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02472353's enrollment target sits among peer trials
30 1582nd of 2000 higher than 332 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia